

## Medical and Behavioral Health Policy Activity

Policies Effective: August 5, 2024    Notification Posted: June 3, 2024

### Policies Developed

None

### Policies Revised

- **Image-Guided Minimally Invasive Decompression for Spinal Stenosis, IV-120**

Image-guided minimally invasive decompression is considered **EXPERIMENTAL/ INVESTIGATIVE** for all indications due to the lack of clinical evidence demonstrating an impact on improved health outcomes.

### Policies Inactivated

- Abatacept, II-161
- Accepted Indications for Medical Drugs Which are not Addressed by a Specific Medical Policy, II-173
- Aducanumab – Commercial, II-253
- Advanced Pharmacologic Therapies for Pulmonary Arterial Hypertension, II-107
- Afamelanotide, II-238
- Agalsidase beta, II-26
- Alemtuzumab, II-184
- Alglucosidase Alfa, II-186
- Alpha-1 Proteinase Inhibitors, II-206
- Anifrolumab, II-255
- Avacincaptad Pegol, II-290
- Avalglucosidase Alfa, II-256
- Axicabtagene Ciloleucel, II-187
- Belimumab, II-152
- Benralizumab, II-203
- Betibeglogene autotemcel, II-267
- Bezlotoxumab, II-199
- Botulinum Toxin, II-16
- Brexanolone, II-231
- Brexucabtagene Autoleucel, II-245
- Burosumab, II-212
- Casimersen, II-251
- Cellular Immunotherapy for Prostate Cancer, II-144
- Cerliponase alfa, II-176
- Certolizumab Pegol, II-179
- Ciltacabtagene Autoleucel, II-262
- Crizanlizumab, II-235
- Delandistrogene moxeparvovec, II-284
- Eculizumab, II-196

- Edaravone, II-178
- Efgartigimod alfa, II-260
- Elivaldogene Autotemcel, II-268
- Elosulfase Alfa, II-218
- Emapalumab, II-204
- Enzyme Replacement Therapy for the Treatment of Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID), II-227
- Epcoritamab, II-283
- Eptinezumab, II-240
- Esketamine, II-226
- Eteplirsen, II-172
- Etranacogene dezaparvovec, II-273
- Evinacumab, II-250
- Exagamglogene autotemcel, II-293
- Fosdenopterin, II-210
- Galsulfase, II-217
- Givosiran, II-234
- Golimumab, II-180
- Golodirsen, II-232
- Idecabtagene Vicleucel, II-252
- Idursulfase, II-215
- Immunoglobulin Therapy, II-51
- Inclisiran, II-258
- Inebilizumab, II-244
- Infliximab, II-97
- Injectable Clostridial Collagenase for Fibroproliferative Disorders, II-145
- Intermittent Intravenous Insulin Therapy, II-189
- Intra-Articular Hyaluronan Injections for Osteoarthritis, II-29
- Intravenous Enzyme Replacement Therapy for Gaucher Disease, II-214
- Intravitreal Angiogenesis Inhibitors for Treatment of Retinal and Choroidal Vascular Conditions, II-71
- Intravitreal Corticosteroid Implants, II-100
- IV Iron Replacement Therapy, II-243
- Laronidase, II-216
- Lecanemab, II-276
- Lisocabtagene Maraleucel, II-249
- Lovotibeglogene autotemcel, II-294
- Lumasiran, II-248
- Luspatercept, II-237
- Lyme Disease: Diagnostic Testing and Intravenous Antibiotic Therapy, II-165
- Medicare Part B Step Therapy, II-247
- Mepolizumab, II-201
- Motixafortide, II-292

- Nadofaragene firadenovec, II-274
- Naltrexone Implants, II-223
- Natalizumab, II-49
- Nusinersen, II-171
- Ocrelizumab, II-185
- Olipudase alfa, II-270
- Omalizumab, II-34
- Onasemnogene Apeparvovec, II-230
- Patisiran, II-220
- Pegcetacoplan, II-277
- Pegloticase, II-147
- Pegunigalsidase alfa, II-281
- Pharmacologic Therapies for Hereditary Angioedema, II-102
- Progesterone Therapy to Reduce Preterm Birth in High-Risk Pregnancies, II-38
- Ravulizumab, II-229
- Reslizumab, II-202
- Respiratory Syncytial Virus (RSV) Prophylaxis, II-62
- Risankizumab, II-265
- Rituximab, II-47
- Romiplostim, II-211
- Romosozumab, II-236
- Rozanolixizumab, II-287
- Sebelipase Alfa, II-200
- Site of Service for Selected Specialty Medical Drugs, XI-06
- Spesolimab, II-269
- Step Therapy Supplement, II-242
- Subcutaneous Hormone Pellets, II-159
- Sutimlimab, II-263
- Teclistimab, II-282
- Teplizumab, II-272
- Teprotumumab, II-239
- Tezepelumab, II-259
- Tidrakizumab, II-222
- Tisagenlecleucel, II-183
- Tocilizumab, II-181
- Tofersen, II-280
- Triamcinolone Acetonide Suprachoroidal Injection, II-257
- Ublituximab, II-275
- Ustekinumab, II-168
- Valoctocogene roxaparvovec, II-286
- Vedolizumab, II-182
- Velmanase alfa, II-278



- Vestronidase Alfa, II-219
- Viltolarsen, II-246
- Voretigene Neparvovec, II-188
- Vutrisiran, II-264

**Policies Delegated to eviCore**  
**None**